What is Delve Bio?
Based in San Francisco, California, Delve Bio operates within the dynamic medtech sector, specializing in advanced metagenomic sequencing technologies. The company's focus on providing sophisticated tools for analyzing complex biological samples positions it at the forefront of genomic research and diagnostics. By enabling deeper insights into microbial communities and their functions, Delve Bio aims to drive advancements in areas such as personalized medicine, environmental monitoring, and infectious disease research. The recent enterprise-level funding indicates a strong market validation for its technological capabilities and strategic vision.
How much funding has Delve Bio raised?
Delve Bio has raised a total of $35M across 1 funding round:
Series A
$35M
Series A (2023): $35M with participation from Section 32, GV, and Xontogeny Venture Fund II
Key Investors in Delve Bio
Section 32
Section 32 is a venture capital firm that focuses on investing in cutting-edge technology, particularly within the life sciences and enterprise sectors. Their investment strategy targets innovative startups and emerging technologies, aiming to support visionary entrepreneurs at the forefront of technological advancement.
GV
GV is a venture capital firm that invests across multiple stages and sectors, with a focus on enterprise solutions, life sciences, and frontier technology innovations. They provide financial backing to promising startups and growth-stage businesses globally.
Xontogeny Venture Fund II
Xontogeny Venture Fund II is an investment entity participating in the funding round, likely focused on supporting early-stage and growth-stage companies within the life sciences and biotechnology sectors.
What's next for Delve Bio?
With the recent influx of major strategic investment, Delve Bio is poised for an accelerated growth trajectory. This capital infusion is expected to fuel further research and development, enhance its technological platform, and expand its market reach. The company's focus on metagenomic sequencing positions it to capitalize on the increasing demand for advanced biological data analysis. Future endeavors will likely involve scaling operations, forging strategic partnerships, and potentially exploring new applications for its sequencing technologies, solidifying its role as a key player in the evolving landscape of genomic medicine and biotechnology.
See full Delve Bio company page
